Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.

about

Targeting RNA helicases in cancer: The translation trap.Abnormal expression of YEATS4 associates with poor prognosis and promotes cell proliferation of hepatic carcinoma cell by regulation the TCEA1/DDX3 axis

P2860

Q47719079-608E8B7A-9F93-40B3-8DA5-AD14436EE44A Q58790046-DA251BBD-A76D-433F-9196-708EA5C7EED8

P2860

Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.

Item

http://www.wikidata.org/entity/Q38718686

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Combination treatment using DD ...... RCA1-proficient breast cancer.

@en

type

Item

label

Combination treatment using DD ...... RCA1-proficient breast cancer.

@en

prefLabel

Combination treatment using DD ...... RCA1-proficient breast cancer.

@en

P1476

Combination treatment using DD ...... RCA1-proficient breast cancer.

@en

P2093

Elsken van der Wall

http://www.w3.org/2001/XMLSchema#string

Farhad Vesuna

http://www.w3.org/2001/XMLSchema#string

Guus M Bol

http://www.w3.org/2001/XMLSchema#string

Justin D Brilliant

http://www.w3.org/2001/XMLSchema#string

Paul J van Diest

http://www.w3.org/2001/XMLSchema#string

Venu Raman

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

DNA resection in eukaryotes: deciding how to fix the break

The DNA-damage response in human biology and disease

Targeting the DNA Damage Response in Cancer

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Brca1 controls homology-directed DNA repair

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein.

P2888

s12032-017-0889-2

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12032-017-0889-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marise R Heerma van Voss

P577

2017-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1074247694

http://www.w3.org/2001/XMLSchema#string

P698

28138868

http://www.w3.org/2001/XMLSchema#string

P932

5576028

http://www.w3.org/2001/XMLSchema#string

Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.

about

P2860

P2860

Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932